Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Archives of Oto-Rhino-Laryngology

Open Access 07-05-2024 | Dystonia | Laryngology

Demographic and clinical characteristics of our patients diagnosed with laryngeal dystonia

Authors: Orhan Asya, Ömer Tarık Kavak, Hatice Ömercikoğlu Özden, Dilek Günal, Necati Enver

Published in: European Archives of Oto-Rhino-Laryngology

Login to get access

Abstract

Purpose

Laryngeal dystonia (LD) is a focal dystonia affecting laryngeal musculature with no known etiology or cure. The present study evaluated the sociodemographic and clinical features of patients diagnosed with LD.

Materials and Methods

All patients diagnosed with LD at our University Hospital’s Ear, Nose, and Throat Department between January 2017 and July 2023 were retrospectively analyzed. The study included 43 patients.

Results

Out of the 43 patients, 19 (44%) were male. At the time of diagnosis, the mean age of the patients was 35.1 years (ranging from 17 to 65 years). The mean elapsed time between the first symptom onset and the first diagnosis was 49.2 months (min. 4 months, max. 240 months). Of the participants, 94% had adductor-type LD. None of the patients had a family history of LD. Of the patients, 9 (20%) experienced a life-altering event or trauma just before the onset of symptoms. All patients who consumed alcohol reported symptom relief with alcohol intake. A total of 67.6% of patients stated that their symptoms were triggered by stress. All of our patients received at least one Botulinum toxin injection, with an average of 2.75 dosages per patient.

Conclusion

The gender distribution was approximately equitable between males and females. There was a tendency for men to receive a diagnosis earlier than women following the manifestation of symptoms. A significant number of patients associate the emergence of their symptoms with a stressful event or traumatic experience. This study represents the initial investigation into the sociodemographic characteristics of patients within the Turkish population.
Literature
1.
Reid EW, Nobriga CV (2022) Spasmodic dysphonia: introductory phonetic analyses. Clin Linguist Phon 37(10):883–98PubMedCrossRef
2.
AB Dds 1988 Clinical and laboratory characteristics of focal laryngeal dystonia: study of 110 cases Laryngoscope 98 6 636 640CrossRef
3.
Aronson A, Bless D (2009) Spasmodic dysphonia, clinical voice disorders. Thieme Medical Publishers, New York
4.
SM Cohen 2012 Prevalence and causes of dysphonia in a large treatment-seeking population Laryngoscope 122 2 343 348PubMedCrossRef
5.
N Roy 2005 Voice disorders in the general population: prevalence, risk factors, and occupational impact Laryngoscope 115 11 1988 1995PubMedCrossRef
6.
7.
A Blitzer 2010 Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series Eur J Neurol 17 28 30PubMedCrossRef
8.
A Blitzer 2018 Phenomenology, genetics, and CNS network abnormalities in laryngeal dystonia: a 30-year experience Laryngoscope 128 S1 S9PubMedCrossRef
9.
10.
U Walter 2014 Sonographic detection of basal ganglia abnormalities in spasmodic dysphonia Eur J Neurol 21 2 349 352PubMedCrossRef
11.
12.
G Defazio A Berardelli M Hallett 2007 Do primary adult-onset focal dystonias share aetiological factors? Brain 130 5 1183 1193PubMedCrossRef
13.
Simonyan K (2017) Inferior parietal cortex as a hub of loss of inhibition and maladaptive plasticity (S39. 002). AAN Enterprises
14.
D Valeriani K Simonyan 2020 A microstructural neural network biomarker for dystonia diagnosis identified by a DystoniaNet deep learning platform Proc Natl Acad Sci 117 42 26398 26405PubMedPubMedCentralCrossRef
15.
M Hyodo 2021 The prevalence and clinical features of spasmodic dysphonia: A review of epidemiological surveys conducted in Japan Auris Nasus Larynx 48 2 179 184PubMedCrossRef
16.
JG Nutt 1988 Epidemiology of focal and generalized dystonia in Rochester, Minnesota Mov Disord 3 3 188 194PubMedCrossRef
17.
AB Patel 2015 The Mayo Clinic Arizona spasmodic dysphonia experience: a demographic analysis of 718 patients Ann Otol Rhinol Laryngol 124 11 859 863PubMedCrossRef
18.
CR Watts M Vanryckeghem 2017 Communication-related affective, behavioral, and cognitive reactions in speakers with spasmodic dysphonia Laryngoscope Investig Otolaryngol 2 6 466 470PubMedPubMedCentralCrossRef
19.
TK Meyer A Hu AD Hillel 2013 Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin Laryngoscope 123 S1 S14PubMedCrossRef
20.
L Sulica A Blitzer 2004 Botulinum toxin treatment of spasmodic dysphonia Oper Tech Otolaryngol Head Neck Surg 15 2 76 80CrossRef
21.
22.
N Isshiki 2001 Thyroplasty for adductor spasmodic dysphonia: further experiences Laryngoscope 111 4 615 621PubMedCrossRef
23.
T Sanuki E Yumoto 2017 Long-term evaluation of type 2 thyroplasty with titanium bridges for adductor spasmodic dysphonia Otolaryngol Head Neck Surg 157 1 80 84PubMedCrossRef
24.
JA Koufman 2006 Treatment of adductor-type spasmodic dysphonia by surgical myectomy: a preliminary report Ann Otol Rhinol Laryngol 115 2 97 102PubMedCrossRef
25.
K Nakamura 2008 Surgical treatment for adductor spasmodic dysphonia–efficacy of bilateral thyroarytenoid myectomy under microlaryngoscopy Acta Otolaryngol 128 12 1348 1353PubMedCrossRef
26.
GS Berke 1999 Selective laryngeal adductor denervationreinnervation: a new surgical treatment for adductor spasmodic dysphonia Ann Otol Rhinol Laryngol 108 3 227 231PubMedCrossRef
27.
28.
Duffey PF et al (1998) The epidemiology of the primary dystonias in the north of England. Adv Neurol 78:121–125PubMed
29.
Group ESoDiEC (2000) A prevalence study of primary dystonia in eight European countries. J Neurol 247:787–792CrossRef
30.
EC Konkiewitz 2002 Service-based survey of dystonia in Munich Neuroepidemiology 21 4 202 206CrossRef
31.
T Pekmezović 2003 Prevalence of primary late-onset focal dystonia in the Belgrade population Mov Disord 18 11 1389 1392PubMedCrossRef
32.
33.
Graham H (2009) Understanding health inequalities. McGraw-Hill Education (UK), London
34.
R Watanabe H Hashimoto 2012 Horizontal inequity in healthcare access under the universal coverage in Japan; 1986–2007 Soc Sci Med 75 8 1372 1378PubMedCrossRef
35.
Van Doorslaer E, Koolman X, Puffer F (2002) Equity in the use of physician visits in OECD countries: has equal treatment for equal need been achieved. Measuring up: improving health system performance in OECD countries
36.
Hintze JM et al (2017) Spasmodic dysphonia: a review. Part 1: pathogenic factors. Otolaryngol Head Neck Surg 157(4):551–557PubMedCrossRef
37.
N Nerurkar T Banu 2014 Spasmodic dysphonia: a seven-year audit of dose titration and demographics in the Indian population J Laryngol Otol 128 7 649 653PubMedCrossRef
38.
39.
L Childs 2011 Patient perceptions of factors leading to spasmodic dysphonia: a combined clinical experience of 350 patients Laryngoscope 121 10 2195 2198PubMedCrossRef
40.
S Tisch 2003 Spasmodic dysphonia: clinical features and effects of botulinum toxin therapy in 169 patients—an Australian experience J Clin Neurosci 10 4 434 438PubMedCrossRef
41.
K Tanner 2011 Spasmodic dysphonia: onset, course, socioemotional effects, and treatment response Ann Otol Rhinol Laryngol 120 7 465 473PubMedCrossRef
42.
43.
44.
S Guiry A Worthley K Simonyan 2019 A separation of innate and learned vocal behaviors defines the symptomatology of spasmodic dysphonia Laryngoscope 129 7 1627 1633PubMedCrossRef
45.
GG Putzel 2018 Polygenic risk of spasmodic dysphonia is associated with vulnerable sensorimotor connectivity Cereb Cortex 28 1 158 166PubMedCrossRef
46.
M Svetel 2007 Spread of primary dystonia in relation to initially affected region J Neurol 254 879 883PubMedCrossRef
47.
de Lima Xavier L, Simonyan K (2019) The extrinsic risk and its association with neural alterations in spasmodic dysphonia. Parkinsonism Relat Disord 65:117–123CrossRef
48.
49.
Sanuki T (2022) Spasmodic dysphonia: an overview of clinical features and treatment options. Auris Nasus Larynx
50.
T Murry GE Woodson 1995 Combined-modality treatment of adductor spasmodic dysphonia with botulinum toxin and voice therapy J Voice 9 4 460 465PubMedCrossRef
Metadata
Title
Demographic and clinical characteristics of our patients diagnosed with laryngeal dystonia
Authors
Orhan Asya
Ömer Tarık Kavak
Hatice Ömercikoğlu Özden
Dilek Günal
Necati Enver
Publication date
07-05-2024
Publisher
Springer Berlin Heidelberg
Published in
European Archives of Oto-Rhino-Laryngology
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-024-08688-9